Drug Trial Radar · NCT03459222
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
229
Actual
Start
May 30, 2018
Primary completion
Feb 19, 2025
Study completion Feb 19, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Conditions
- Advanced Cancer
Interventions
RelatlimabBiological
Specified dose on specified days
NivolumabBiological
Specified dose on specified days
BMS-986205Drug
Specified dose on specified days
IpilimumabBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Grade 3/Grade 4 Laboratory Test ResultsTime frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
- Number of Participants With Adverse Events and DeathsTime frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
- Number of Participants With Dose Limiting ToxicitiesTime frame: From first dose (Day 1) and up to 42 days post first dose
- Objective Response Rate (ORR)Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
- Disease Control Rate (DCR)Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
- Duration of Response (DoR)Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
Local Institution - 0006
Duarte, California
Local Institution - 0003
Aurora, Colorado
Local Institution - 0004
Baltimore, Maryland
Local Institution - 0005
St Louis, Missouri
Local Institution - 0001
Germantown, Tennessee
Local Institution - 0012
Wollstonecraft, New South Wales, Australia
Local Institution - 0011
Nedlands, Western Australia, Australia
Local Institution - 0017
Marseille, France
Local Institution - 0016
Toulouse, France
Local Institution - 0015
Villejuif, France
Local Institution - 0010
Forlì, Italy
Local Institution - 0009
Naples, Italy
Local Institution - 0023
Rome, Italy
Local Institution - 0019
Barcelona, Spain
Local Institution - 0021
Madrid, Spain
Local Institution - 0018
Madrid, Spain
Local Institution - 0022
Málaga, Spain
Local Institution - 0020
Pamplona, Spain
Local Institution - 0008
Lausanne, Switzerland
Local Institution - 0007
Zurich, Switzerland
Local Institution - 0013
Headington, United Kingdom
Local Institution - 0014
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.